Vanguard Group Inc Navidea Biopharmaceuticals, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.08 - $0.29 $811 - $2,942	-10,147 Reduced 3.54%	276,491 $24,000
Q1 2023 May 15, 2023	SELL	$0.24 - $0.34 $91,464 - $129,574	-381,102 Reduced 57.07%	286,638 $74,000
Q4 2022 Feb 10, 2023	SELL	$0.18 - $0.3 $8,170 - $13,616	-45,389 Reduced 6.36%	667,740 $140,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $0.71 $5,710 - $16,893	-23,794 Reduced 3.23%	713,129 $181,000
Q4 2021 Feb 14, 2022	SELL	$1.0 - $1.82 $1,438 - $2,617	-1,438 Reduced 0.19%	736,923 $737,000
Q3 2021 Nov 12, 2021	BUY	$1.53 - $1.85 $13,158 - $15,910	8,600 Added 1.18%	738,361 $1.29 Million
Q2 2021 Aug 13, 2021	BUY	$1.55 - $2.15 $1.13 Million - $1.57 Million	729,761 New	729,761 $1.34 Million

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.